| Features: |
| ONC201 (Dordaviprone; Modeyso) — Orally active, brain-penetrant imipridone anticancer drug with dual activity as an allosteric agonist of the mitochondrial protease ClpP and antagonist of dopamine D2/D3 receptors (DRD2/DRD3). ONC201 disrupts mitochondrial metabolism, activates cellular stress responses, suppresses pro-survival signaling, and promotes tumor-cell apoptosis. Drug class: Targeted anticancer therapy / mitochondrial protease activator / imipridone. ONC201 is an antineoplastic drug but is not conventional cytotoxic chemotherapy. Primary cancer relevance: Strongest for diffuse midline glioma harboring an H3 K27M mutation. In August 2025, dordaviprone received FDA accelerated approval for adult and pediatric patients age 1 year and older with progressive H3 K27M-mutant diffuse midline glioma following prior therapy. Primary mechanism: ClpP activation → mitochondrial proteolysis and metabolic dysfunction ↑ → integrated stress response ↑ → apoptosis ↑. ONC201 also antagonizes DRD2/DRD3 and can suppress downstream AKT and MAPK/ERK survival signaling. Typical target/pathway effects: CLPP activation ↑; DRD2 antagonism; DRD3 antagonism; mitochondrial respiration/metabolism ↓; integrated stress response ↑; ATF4 ↑; CHOP/DDIT3 ↑; AKT signaling ↓; MAPK/ERK signaling ↓; apoptosis ↑; tumor-cell proliferation ↓. H3 K27M relevance: H3 K27M-mutant diffuse midline glioma appears particularly sensitive to ONC201/dordaviprone. Treatment has been associated with restoration of H3K27 trimethylation and durable responses in a subset of patients. Clinical evidence: FDA accelerated approval was based on an integrated population of patients with recurrent/progressive H3 K27M-mutant diffuse midline glioma. The objective response rate was approximately 22%, with a median response duration of approximately 10.3 months. Typical adult clinical dose: 625 mg orally once weekly for the FDA-approved indication. |
| 8641- | MBZ, | ONC201, | The therapeutic potential of repurposed mebendazole, alone and in synergistic combination with ONC201, in the treatment of diffuse midline glioma |
| - | in-vitro, | GBM, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:492 Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid